^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | OBX02-011 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5350 - OBX02-011, a reversible fourth-generation EGFR-TKI, overcomes C797S-mediated resistance in non-small cell lung cancer
Published date:
03/09/2022
Excerpt:
we reported the discovery and preclinical efficacy of OBX02-011, fourth EGFR-TKI targeting overcome EGFR C797S mutation...this agent showed potent anticancer effects and the inhibition of EGFR-related signaling in various models including EGFR C797S mutation. Additionally, we evaluated the efficacy of OBX02-011 in transgenic models (EGFRL858R+T790M+C797S), showing the enhanced survival, and inhibition of tumor growth and EGFR activity. Collectively, our data suggest that OBX02-011 may be promising new EGFR-TKI to overcome C797S-mediated resistance in NSCLC.
